NanoViricides (OTC:NNVC) is a company that holds more than one promising clinical development programs under its belt, with its most advanced - FluCide - set to undergo FDA scrutiny in an upcoming pre-investigational new drug (IND) application meeting in March.

Bacterin (AMEX:BONE) received Wednesday initial analyst coverage from Northland Capital Markets, which started the developer of bone graft material and antimicrobial coatings with an outperform rating and a bullish $4.80 price target.

Life sciences company Pressure BioSciences (NASDAQ:PBIO) has seen a host of developments of late, including the successful raising of nearly $1 million and meeting its sales targets for the third quarter, putting the company on pace for steady growth in 2012.

Pressure BioSciences (PBI) (NASDAQ:PBIO) is a company operating in the life sciences market, whose pressure cycling technology (PCT) used to extract cell components has a myriad of potential target industries, and according to CEO Richard T. Schumacher, is among the most under-appreciated businesses listed on the Nasdaq today, with enormous growth potential.

The New England Journal of Medicine (NEJM) published a letter from prominent leukemia specialist and Key Opinion Leader, Dr. Ayalew Tefferi critiquing the efficacy and long-term safety of Incyte Pharmaceutical’s first in class JAK inhibitor, ruxolitinib. That day, Incyte’s stock dropped 6.8% on twice the usual volume.